Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | MST1R | Q04912 | 3/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | HGF | P14210 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1549776 | 0.86 | MET (0.48) | METKDRMST1RPDGFRAAXL | |
| SCHEMBL28512289 | 0.84 | MET (0.47) | METKDRMST1RPDGFRAPDGFRB | |
| SCHEMBL1549363 | 0.84 | MET (0.43) | METKDRMST1RPDGFRAHGF | |
| SCHEMBL2335546 | 0.82 | KDR (0.49) | METKDRMST1RPDGFRAAXL | |
| SCHEMBL28907136 | 0.80 | MET (0.48) | METKDRMST1RPDGFRAAXL | |
| SCHEMBL4483017 | 0.79 | MET (0.55) | METKDRMST1RPDGFRAHGF | |
| SCHEMBL371803 | 0.79 | MET (0.55) | METKDRMST1RPDGFRAHGF | |
| SCHEMBL30713842 | 0.79 | MET (0.55) | METKDRMST1RPDGFRAHGF | |
| SCHEMBL28530276 | 0.78 | MET (0.45) | METKDRMST1RPDGFRAAXL | |
| SCHEMBL1876626 | 0.78 | AXL (0.54) | METKDRPDGFRAPDGFRBAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108864050-B | Method for synthesizing Arotinib and hydrochloride thereof | 上海博璞诺科技发展有限公司 | 2019-12-10 | — | — | CN | claimed |
| CN-108864050-B | Method for synthesizing Arotinib and hydrochloride thereof | 上海博璞诺科技发展有限公司 | 2019-12-10 | — | — | CN | disclosed |
| EP-2312950-B1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LAB LLC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-8211911-B2 | Compounds as kinase inhibitors | CHEN GUOQING PAUL (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211911-B2 | Compounds as kinase inhibitors | CHEN GUOQING PAUL (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100048599-A1 | Compounds As Kinase Inhibitors | CHEN GUOQING PAUL | 2010-02-25 | — | — | US | disclosed |
| US-20100048599-A1 | Compounds As Kinase Inhibitors | CHEN GUOQING PAUL | 2010-02-25 | — | — | US | disclosed |
| WO-2010021918-A1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048599-A1 | Compounds As Kinase Inhibitors | MAP3K1, MAP3K5, MAP3K6 | MET 472/4885KDR 44/4885MST1R 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.